secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRONWOOD PHARMACEUTICALS INC (IRWD)
CIK:        0001446847
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001104659-23-055770
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ironwood Q1 2023: net income $45.7M ($0.30 EPS); LINZESS demand up 10% YoY
--------------------------------------------------------------------------

- Total revenues $104.1M, up 7% YoY; GAAP net income $45.7M vs $38.8M.
- LINZESS U.S. net sales $250M (+8% YoY); prescription demand grew 10% YoY.
- Ended Q1 with $740M cash; full-year 2023 financial guidance maintained.
- PDUFA date June 14 for potential pediatric functional constipation indication in ages 6-17.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1446847/000110465923055770/0001104659-23-055770-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1446847/000110465923055770/tm2314422d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-055770

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer